Pharvaris (NASDAQ:PHVS) dominated the clinical spotlight at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 meeting on Monday, unveiling full data from its RAPIDe-3 and CHAPTER-1 trials.
The results provide a compelling case for deucrictibant as the first oral therapy capable of delivering the rapid efficacy typically reserved for injectable treatments in both on-demand and prophylactic HAE settings.
The pivotal Phase 3 RAPIDe-3 study, which evaluated a 20 mg immediate-release capsule for on-demand treatment, met its primary endpoint and all 11 secondary efficacy endpoints with high statistical significance.
Median time to onset of symptom relief was 1.28 hours for deucrictibant versus over 12 hours for placebo.
Median time to complete symptom resolution was 11.95 hours, compared to more than 48 hours for the placebo group.
The "End of Progression™"—the moment symptoms stop worsening—occurred in a median of 17.47 minutes, while 93.2% of treated attacks required no rescue medication.
Simultaneously, Pharvaris shared final data from the CHAPTER-1 Phase 2 open-label extension (OLE), reinforcing deucrictibant’s role in long-term prevention.